These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 12812198)

  • 1. Weight-based ribavirin with pegylated interferon alfa 2b: benefits, risks, and the origin of the evidence.
    Hrachovec J; Patel P
    Gastroenterology; 2003 Jun; 124(7):2003-4; author reply 2004-5. PubMed ID: 12812198
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversal of cirrhosis: evidence-based medicine?
    Desmet VJ; Roskams T
    Gastroenterology; 2003 Aug; 125(2):629-30; author reply 630-31. PubMed ID: 12891578
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.
    Poynard T; McHutchison J; Manns M; Trepo C; Lindsay K; Goodman Z; Ling MH; Albrecht J
    Gastroenterology; 2002 May; 122(5):1303-13. PubMed ID: 11984517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
    Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response.
    Pearlman BL; Ehleben C
    Hepatology; 2010 Oct; 52(4):1519-20; author reply 1520-1. PubMed ID: 20879035
    [No Abstract]   [Full Text] [Related]  

  • 6. Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C.
    Kanda T; Yokosuka O
    JNMA J Nepal Med Assoc; 2011; 51(181):41-8. PubMed ID: 22335095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracerebral hemorrhage in a patient receiving combination therapy of pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
    Nishiofuku M; Tsujimoto T; Matsumura Y; Toyohara M; Yoshiji H; Yamao J; Fukui H; Yoshikawa M
    Intern Med; 2006; 45(7):483-4. PubMed ID: 16679707
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschr Med; 2002 Sep; 144(38):59. PubMed ID: 12395712
    [No Abstract]   [Full Text] [Related]  

  • 9. Which is the real efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in HCV infected patients with advanced fibrosis?
    Pellicelli AM; Romano M; Guarascio P; Vignally P
    J Hepatol; 2012 Sep; 57(3):704-5. PubMed ID: 22510262
    [No Abstract]   [Full Text] [Related]  

  • 10. Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
    Santin M; Shaw E
    Lancet; 2002 Jan; 359(9302):263; author reply 264. PubMed ID: 11812596
    [No Abstract]   [Full Text] [Related]  

  • 11. Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
    Cecil BD
    Lancet; 2002 Jan; 359(9302):263-4. PubMed ID: 11812598
    [No Abstract]   [Full Text] [Related]  

  • 12. Progress on the treatment of hepatitis C.
    Nierengarten MB
    Lancet Infect Dis; 2003 Dec; 3(12):748. PubMed ID: 14664249
    [No Abstract]   [Full Text] [Related]  

  • 13. Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
    Picon PD; Costa AF; Kuchenbecker R; Beltrame A
    Lancet; 2002 Jan; 359(9302):263; author reply 264. PubMed ID: 11812597
    [No Abstract]   [Full Text] [Related]  

  • 14. [Triple therapy with direct acting antiviral agent, peginterferon and ribavirin for chronic hepatitis C].
    Izumi N; Kurosaki M; Suzuki S; Tamaki N
    Nihon Shokakibyo Gakkai Zasshi; 2012 Dec; 109(12):2108-11. PubMed ID: 23221060
    [No Abstract]   [Full Text] [Related]  

  • 15. Do differences in pegylation of interferon alfa matter?
    Zeuzem S
    Gastroenterology; 2010 Jan; 138(1):34-6. PubMed ID: 19932662
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatitis C viral kinetics as a determinant of stopping pegylated interferon and ribavirin in genotype 1 infection.
    Kim DY
    Gut Liver; 2014 Jul; 8(4):335-6. PubMed ID: 25071896
    [No Abstract]   [Full Text] [Related]  

  • 17. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
    Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
    Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus.
    Tamai H; Shingaki N; Mori Y; Moribata K; Kawashima A; Maeda Y; Niwa T; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Ichinose M
    Gut Liver; 2016 Jul; 10(4):617-23. PubMed ID: 26601828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of PEG-interferon alfa-2a plus ribavirin as treatment for chronic HCV hepatitis in a child cured of ALL.
    Lo Nigro L; La Spina M; Mirabile E; Pisana P; Schilirò G; Guardo P
    Pediatr Blood Cancer; 2004 Aug; 43(2):185. PubMed ID: 15236293
    [No Abstract]   [Full Text] [Related]  

  • 20. [New therapeutic agents for chronic hepatitis C].
    Hiramatsu N; Hayashi N
    Nihon Naika Gakkai Zasshi; 2004 Jan; 93(1):170-7. PubMed ID: 14968593
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.